Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of ACT-01 in acute optic neuritis
2020-003147-29Phase 2Completed
- Sponsor
- ACCURE TX FRANCE SASU
- Start
- Jul 2020
- Modality
- Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in optic neuritis (ON) comparing ACT-01 with Placebo (2 arms). Primary endpoint: Primary safety and tolerability at month 6. Started Jul 2020; status: completed.
02
Drugs
privosegtor
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on 2020-003147-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003147-29.